Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 79INDUSTRY 53NIH 17NETWORK 11OTHER_GOV 2UNKNOWN 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Breast Neoplasms 17Uterine Cervical Neoplasms 11Stomach Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 8Neoplasms 8Esophageal Neoplasms 8Carcinoma, Ovarian Epithelial 7Fallopian Tube Neoplasms 6Colorectal Neoplasms 5Recurrence 4Neoplasm Metastasis 4Multiple Myeloma 4Mouth Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Hepatocellular 4Rectal Neoplasms 3Nasopharyngeal Carcinoma 3Lymphoma, Non-Hodgkin 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Glioblastoma 3Esophageal Squamous Cell Carcinoma 3Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Polycystic Ovary Syndrome 2Peripheral Nervous System Diseases 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × OTHER_GOV × Lymphoma, Large B-Cell, Diffuse × Clear all
NCT05164770 2021-12-21

Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Shandong Provincial Hospital

Phase 3 Unknown
160 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05097443 2021-11-19

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Shandong Provincial Hospital

Phase 3 Unknown
130 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡